ANZCTR search results

This study aims to look at a new ultrasound machine that has been purpose-designed to evaluate perfusion (blood flow through tissues). We have previously established normal ranges for a technique to measure three-dimensional ultrasound volumes called 3D Fractional Moving Blood Volume, using commercially available ultrasound machinery (GE Voluson E10). We now want to look at paired evaluations of fetal brain, kidney, liver and placental perfusion using our new machine along with the GE Voluson E10. We hypothesise that our new machine will take stable measurements of organ perfusion that will be comparable to the existing commercial machinery.

This pilot study aims to reveal the profiles of extracellular vesicles (EVs) in periodontal patients, with uncontrolled T2DM and without T2DM/well-controlled T2DM (refers to diseased groups) before and after treatment follow-up (3, 6 months). EVs from non-diabetic/ well controlled T2DM patients (without follow-ups as no need to follow up) will be used as controls. Whole oral samples (saliva, GCF and plaque) will be used as controls. There are two general aims for this project: Aim 1: Diagnosis values of host and microbial EVs in periodontitis patients with and without T2DM Compare the differences in host and microbial derived EVs and their EV content expressions between periodontitis+ T2DM and periodontitis patients undergoing treatment over a 6-month observation period. Aim 2: To correlate host and microbial EVs contents with clinical outcomes in periodontitis patients with and without T2DM Correlate EVs expression levels with all clinical outcomes to distinguish between responders and non-responders to determine the prognosis power of EVs. It is hypothesised that host and microbial EVs and EV content are differentially expressed in patients with uncontrolled T2Dm compared with non-diabetic/well-controlled T2DM patients, and correlates with the severity of periodontitis. Furthermore, it is hypothesised that EVs will be positively correlated with improvements in clinical parameters after periodontal or T2DM treatment.

Cardiac catheter ablation is a common treatment for heart rhythm disorders. Catheters are long flexible tubes with electrodes at the tip placed in the heart and deliver heating or cooling thermal injury to disrupt abnormal electrical circuits in the heart (ablation). Many of these circuits are located near the atrioventricular node (AVN), an integral structure of the cardiac electrical system. It is the only normal electrical connection between the top and bottom chambers of the heart maintaining synchronised contraction. Inadvertent damage to the AVN through heating or cooling of nearby structures can result in heart block, requiring pacemaker insertion. This study aims to measure the temperature at the AVN during ablations with a temperature sensor catheter to further understand the AVN properties and reduce the risk of heart block by alerting of its impending damage. This study will assess 2 patient groups; Group 1 will undergo intentional clinically indicated ablation of the AVN with pacemakers in-situ, Group 2 will undergo supraventricular tachycardia (a fast heart rhythm condition) ablations where electrical circuits are located near the AVN. During ablation, electrical measurements will be taken and correlated with AVN temperature. We predict during ablation, the temperature sensing catheter placed at the AVN will detect temperature changes and alter AVN electrical properties which may forewarn operators of imminent heart block, indicative of AVN damage. These findings have potential to enhance patient safety during cardiac ablations, change clinical practice and improve our understanding of the AVN and its properties.

Ear disease, and its associated hearing loss, are more prevalent in Aboriginal and Torres Strait Islander children. While ear and hearing health services are available, it can be hard for families to attend these services. This project seeks a clear understanding of the out of pocket health care expenditure and referral process from the perspectives of Aboriginal and/or Torres Strait Islander parents and families of young children between the ages of 0 - 8 years with a history of ear disease.

The purpose of this study is to evaluate if treatment with epcoritamab will improve outcomes compared with historical value through increased conversion to U-MRD4 (cohort 1) and reduced loss of U-MRD4 (cohort 2) for patients diagnosed with CLL. Who is it for? You may be eligible for this study if you are aged 18 and above and have been diagnosed with CLL or SLL Study details This is a multi-centre single arm non-randomised phase II study in 2 distinct cohorts of patients: Cohort 1: Patients that are MRD4+ (defined as >10-4 on peripheral blood samples) at 3 months after completion of Ven-Obin, irrespective of pre-treatment genomics. Cohort 2: Patients with CLL with adverse-risk genomics (defined as TP53 aberrancy and/or unmutated IGHV) detected before treatment and achieving undetectable MRD4 (U-MRD4) at 3 months following completion of Ven-Obin induction. Both cohorts will receive the following treatment: - Epcoritamab will be administered as a subcutaneous injection on a 28-day cycle. In Cycle 1 epcoritamab will be administered on days 1, 8, 15 and 22, following the ramp-up schedule. - From cycle 2 onwards, epcoritamab will be administered on day 1 of each cycle. During treatment, patients will have the following assessments : · Haematology: Haemoglobin, WBC, Platelets · Biochemistry: Urea, creatinine and electrolytes · Assess AEs A total of 38 patients is planned, 14 in cohort 1 and 24 in cohort 2. Each patient will be followed for 4 years post completion of trial treatment, unless withdrawn previously. The total trial duration is expected to be 7 years. All treatment will be administered by the study team. Drug accountability will be performed by the administering institutions to assess compliance. It is hoped this research will determine if Epcoritamab treatment can improve outcomes for patients diagnosed with CLL.

Patients with a restrictive cardiomyopathy, such as in cardiac amyloidosis, have poor heart function due to the increased stiffness of their heart. These patients usually compensate by increasing their heart rate. In patients with pacemakers, the ability to increase their own heart rate naturally is usually impaired. This trial is aiming to assess if using the pacemaker to increase the patient's heart rate results in better heart function and quality of life in patients with cardiac amyloidosis who have pacemakers. It is hypothesized that patients with an accelerated pacemaker rate will have an improvement in the function of their heart and quality of life compared to those with a lower pacemaker rate.

This study is looking at a new experimental approach for transferring patients from methadone to CAM2038. The purpose of the study is to test if patients with opioid dependence who are treated with a methadone dose of above 30 mg per day to 100 mg per day can be transferred to CAM2038 without reducing the dose of methadone before they start CAM2038. After starting CAM2038 treatment, the methadone dose is then reduced over several days. The main outcome of the study is to see how many participants that proceed to the standard treatment dosing with CAM2038 after one week of treatment with both CAM2038 and methadone. The study hypothesis is that patients can start treatment with CAM2038 without having to reduce their methadone dose below 30 mg before the first dose of CAM2038.

This will be a multicentre (4 Australian HITH services) prospective cohort study where the patient population will be Hospital in the Home (HITH) patients prescribed short term (<2 weeks) continuous antibiotics as an infusion via a Peripheral Intravenous Cannula (PIVC). Patient demographics and comorbidities will be recorded along with prospective data collection on initial PIVC insertion reason and process details, with PIVC and patient outcomes recorded until the time of PIVC removal. A written, short patient survey will also be conducted to establish patient perception and satisfaction of this type of treatment. This means of continuous intravenous antibiotic infusion via a PIVC will be compared to anticipated PIVC complication rates generally (PIVC inserted for any reason) as reported in the literature and to anticipated Peripherally Inserted Central Catheter (PICC) complication rates.

This research study is looking at the ability of the Roche Diagnostics cobas Liat device to reliably and accurately detect Group A Strep (GAS) infection in skin sores. Currently, this device is approved for testing of GAS throat infections. Throat and skin infection with GAS bacteria is common in childhood, but repeated infections can lead to Acute Rheumatic Fever (ARF) and Rheumatic Heart Disease (RHD). Early diagnosis and therefore treatment of GAS infections are key to preventing ARF and RHD, particularly in places with high rates of infections. Analysed and deidentified results from this study will be shared with the study collaborator to support their submission of an application to the Therapeutic Goods Administration to obtain approval for this test to be implemented in clinics for detecting skin infections across Australia.

This study will evaluate a novel intervention designed to help people with a brain tumour better manage their fatigue. Who is it for? You may be eligible for this study if you are an adult with a confirmed diagnosis of a malignant primary brain tumour. Study details Participants will be randomly assigned to either an online program addressing cancer-related fatigue, or an online relaxation program. Both programs will consist of six 30-minutes sessions designed to be completed over 12 weeks. Participants will be asked to complete questionnaires and interviews focused on fatigue self-management and quality of life. It is hoped that findings from this study will contribute towards designing evidence-based interventions to address cancer-related fatigue for people living with a primary brain tumour.